Related Experiment Video
Updated: Jun 11, 2026
Development of Recombinant Proteins to Treat Chronic Pain
Published on: April 11, 2018
[Expression, purification and bioactivity evaluation of streptavidin-tagged human interleukin-21 fusion protein]
Ping-ping Fa1, Zhen Zhang, Jin-long Li
1Institute of Biotherapy, School of Biotechnology, Southern Medical University, Guangzhou 510515, China. fapingping@sohu.com
Objective:
To obtain streptavidin-tagged human interleukin-21 (hIL21) fusion protein and evaluate its bioactivities.
Methods:
hIL21-SA-pET21 and pET24a-SA- hIL21 plasmids were constructed and expressed in BL21(DE3) host bacteria. The hIL21-SA and SA- hIL21 fusion protein were purified through Ni-NTA affinity chromatography and refolded by dialysis. Flow cytometry was used to detect hIL21-SA and SA- hIL21 fusion protein on the biotinylated MB49 tumor cells. MTT assay was used to evaluate the effect of the fusion protein on the proliferation of human peripheral blood lymphocytes (PBLs) stimulated by Anti-CD3.
Results:
The recombinant fusion proteins were highly expressed in BL21(DE3) at about 30% of the total bacterial proteins. The two fusion proteins exhibited bifunctional activities, i.e. both biotin-binding property and hIL21 activity and SA-mediated high-affinity binding to biotinylated cell surfaces (with anchoring modified rate of about 95.18% and 96.91%).
Conclusion:
We have successfully obtained bifunctional fusion protein hIL21-SA and SA- hIL21,which will provide a basis for further study of tumor biotherapy using the proteins.
